Selected research
Industry Research
DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Research Report 2026
Market perspective
The global DPP-4 Inhibitors for Type 2 Diabetes Treatment market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for DPP-4 Inhibitors for Type 2 Diabetes Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for DPP-4 Inhibitors for Type 2 Diabetes Treatment is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for DPP-4 Inhibitors for Type 2 Diabetes Treatment is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of DPP-4 Inhibitors for Type 2 Diabetes Treatment include Novartis, Merck, Eli Lilly and Company, AstraZeneca, Takeda Pharmaceutical, Sanwa Kagaku Kenkyusho, Mitsubishi Tanabe Pharma, LG Life Sciences and Dong-A Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global DPP-4 Inhibitors for Type 2 Diabetes Treatment market in terms of revenue (US$ million) and, where applicable, sales volume (M Pcs), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/M Pcs) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
DPP-4 Inhibitors for Type 2 Diabetes Treatment Market by Company
Novartis
Merck
Eli Lilly and Company
AstraZeneca
Takeda Pharmaceutical
Sanwa Kagaku Kenkyusho
Mitsubishi Tanabe Pharma
LG Life Sciences
Dong-A Pharmaceuticals
Bristol-Myers Squibb
Boehringer Ingelheim
DPP-4 Inhibitors for Type 2 Diabetes Treatment Segment by Type
Alogliptin
Linagliptin
Saxagliptin
Vildagliptin
Sitagliptin
Others
DPP-4 Inhibitors for Type 2 Diabetes Treatment Segment by Application
Hospitals and Clinics
Offline Retail Pharmacy
E-commerce and Internet Medical Care
DPP-4 Inhibitors for Type 2 Diabetes Treatment Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global DPP-4 Inhibitors for Type 2 Diabetes Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of DPP-4 Inhibitors for Type 2 Diabetes Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of DPP-4 Inhibitors for Type 2 Diabetes Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of DPP-4 Inhibitors for Type 2 Diabetes Treatment manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of DPP-4 Inhibitors for Type 2 Diabetes Treatment by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of DPP-4 Inhibitors for Type 2 Diabetes Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Alogliptin
- Linagliptin
- Saxagliptin
- Vildagliptin
- Sitagliptin
- Others
Applications
- Hospitals and Clinics
- Offline Retail Pharmacy
- E-commerce and Internet Medical Care
Companies covered
- Novartis
- Merck
- Eli Lilly and Company
- AstraZeneca
- Takeda Pharmaceutical
- Sanwa Kagaku Kenkyusho
- Mitsubishi Tanabe Pharma
- LG Life Sciences
- Dong-A Pharmaceuticals
- Bristol-Myers Squibb
- Boehringer Ingelheim
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size (2021-2032)
- 2.2.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (2021-2032)
- 2.2.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Average Price (2021-2032)
- 2.3 DPP-4 Inhibitors for Type 2 Diabetes Treatment by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Alogliptin
- 2.3.3 Linagliptin
- 2.3.4 Saxagliptin
- 2.3.5 Vildagliptin
- 2.3.6 Sitagliptin
- 2.3.7 Others
- 2.4 DPP-4 Inhibitors for Type 2 Diabetes Treatment by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospitals and Clinics
- 2.4.3 Offline Retail Pharmacy
- 2.4.4 E-commerce and Internet Medical Care
3 Market Competitive Landscape by Manufacturers
- 3.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs) of Manufacturers (2021-2026)
- 3.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue of Manufacturers (2021-2026)
- 3.4 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Average Price by Manufacturers (2021-2026)
- 3.5 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of DPP-4 Inhibitors for Type 2 Diabetes Treatment, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of DPP-4 Inhibitors for Type 2 Diabetes Treatment, Product Type & Application
- 3.8 Global Manufacturers of DPP-4 Inhibitors for Type 2 Diabetes Treatment, Established Date
- 3.9 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novartis
- 4.1.1 Novartis Company Information
- 4.1.2 Novartis Business Overview
- 4.1.3 Novartis DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novartis DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
- 4.1.5 Novartis Recent Developments
- 4.2 Merck
- 4.2.1 Merck Company Information
- 4.2.2 Merck Business Overview
- 4.2.3 Merck DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Merck DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
- 4.2.5 Merck Recent Developments
- 4.3 Eli Lilly and Company
- 4.3.1 Eli Lilly and Company Company Information
- 4.3.2 Eli Lilly and Company Business Overview
- 4.3.3 Eli Lilly and Company DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Eli Lilly and Company DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
- 4.3.5 Eli Lilly and Company Recent Developments
- 4.4 AstraZeneca
- 4.4.1 AstraZeneca Company Information
- 4.4.2 AstraZeneca Business Overview
- 4.4.3 AstraZeneca DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 AstraZeneca DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
- 4.4.5 AstraZeneca Recent Developments
- 4.5 Takeda Pharmaceutical
- 4.5.1 Takeda Pharmaceutical Company Information
- 4.5.2 Takeda Pharmaceutical Business Overview
- 4.5.3 Takeda Pharmaceutical DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Takeda Pharmaceutical DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
- 4.5.5 Takeda Pharmaceutical Recent Developments
- 4.6 Sanwa Kagaku Kenkyusho
- 4.6.1 Sanwa Kagaku Kenkyusho Company Information
- 4.6.2 Sanwa Kagaku Kenkyusho Business Overview
- 4.6.3 Sanwa Kagaku Kenkyusho DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Sanwa Kagaku Kenkyusho DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
- 4.6.5 Sanwa Kagaku Kenkyusho Recent Developments
- 4.7 Mitsubishi Tanabe Pharma
- 4.7.1 Mitsubishi Tanabe Pharma Company Information
- 4.7.2 Mitsubishi Tanabe Pharma Business Overview
- 4.7.3 Mitsubishi Tanabe Pharma DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Mitsubishi Tanabe Pharma DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
- 4.7.5 Mitsubishi Tanabe Pharma Recent Developments
- 4.8 LG Life Sciences
- 4.8.1 LG Life Sciences Company Information
- 4.8.2 LG Life Sciences Business Overview
- 4.8.3 LG Life Sciences DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 LG Life Sciences DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
- 4.8.5 LG Life Sciences Recent Developments
- 4.9 Dong-A Pharmaceuticals
- 4.9.1 Dong-A Pharmaceuticals Company Information
- 4.9.2 Dong-A Pharmaceuticals Business Overview
- 4.9.3 Dong-A Pharmaceuticals DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Dong-A Pharmaceuticals DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
- 4.9.5 Dong-A Pharmaceuticals Recent Developments
- 4.10 Bristol-Myers Squibb
- 4.10.1 Bristol-Myers Squibb Company Information
- 4.10.2 Bristol-Myers Squibb Business Overview
- 4.10.3 Bristol-Myers Squibb DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Bristol-Myers Squibb DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
- 4.10.5 Bristol-Myers Squibb Recent Developments
- 4.11 Boehringer Ingelheim
- 4.11.1 Boehringer Ingelheim Company Information
- 4.11.2 Boehringer Ingelheim Business Overview
- 4.11.3 Boehringer Ingelheim DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Boehringer Ingelheim DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
- 4.11.5 Boehringer Ingelheim Recent Developments
5 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Scenario by Region
- 5.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region: 2021-2032
- 5.2.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region: 2021-2026
- 5.2.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region: 2027-2032
- 5.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Region: 2021-2032
- 5.3.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Region: 2021-2026
- 5.3.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Region: 2027-2032
- 5.4 North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Facts & Figures by Country
- 5.4.1 North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2032)
- 5.4.3 North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Facts & Figures by Country
- 5.5.1 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2032)
- 5.5.3 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Facts & Figures by Country
- 5.6.1 Asia Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2032)
- 5.6.3 Asia Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Facts & Figures by Country
- 5.7.1 South America DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2032)
- 5.7.3 South America DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Facts & Figures by Country
- 5.8.1 Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2032)
- 6.1.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2032) & (M Pcs)
- 6.1.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2021-2032)
- 6.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2021-2032)
- 6.2.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Type (2021-2032)
- 6.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2032)
- 7.1.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2032) & (M Pcs)
- 7.1.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2021-2032)
- 7.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2021-2032)
- 7.2.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Application (2021-2032)
- 7.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 DPP-4 Inhibitors for Type 2 Diabetes Treatment Value Chain Analysis
- 8.1.1 DPP-4 Inhibitors for Type 2 Diabetes Treatment Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 DPP-4 Inhibitors for Type 2 Diabetes Treatment Production Mode & Process
- 8.2 DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 DPP-4 Inhibitors for Type 2 Diabetes Treatment Distributors
- 8.2.3 DPP-4 Inhibitors for Type 2 Diabetes Treatment Customers
9 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Analyzing Market Dynamics
- 9.1 DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Trends
- 9.2 DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Drivers
- 9.3 DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Opportunities and Challenges
- 9.4 DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst